Compare SPWH & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPWH | ANVS |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 69.1M |
| IPO Year | 2014 | 2019 |
| Metric | SPWH | ANVS |
|---|---|---|
| Price | $1.42 | $2.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.94 | ★ $13.50 |
| AVG Volume (30 Days) | 912.8K | ★ 1.1M |
| Earning Date | 06-02-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,209,182,000.00 | N/A |
| Revenue This Year | $2.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $1.08 | $1.54 |
| 52 Week High | $4.33 | $5.50 |
| Indicator | SPWH | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 59.03 |
| Support Level | $1.30 | $2.29 |
| Resistance Level | $1.51 | $2.67 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 25.00 | 87.57 |
Sportsman's Warehouse Holdings Inc together with its subsidiaries operates as an outdoor sporting goods retailer. It provides a one-stop shopping experience that equips customers with the right quality, brand name hunting, shooting, fishing, and camping gear to maximize enjoyment of the outdoors. The company offers products in the categories of Camping, Apparel, Fishing, Footwear, Hunting and shooting, and Optics, Electronics, Accessories, and Other products. It provides products such as Backpacks, Jackets, Camp essentials, Hiking boots, GPS devices, ATV accessories and Fishing rods, among others. The company also offers an e-commerce experience, extensive in-store events and educational programming.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.